

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Touyun Biotech Group Limited
透雲生物科技集團有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 1332)

**PRECAUTIONARY MEASURES FOR
THE ANNUAL GENERAL MEETING TO BE HELD ON 2 JUNE 2022**

References are made to the Notice of Annual General Meeting (the “AGM”) of Touyun Biotech Group Limited (the “Company”) and the circular (the “Circular”) to shareholders of the Company (the “Shareholders”) both dated 29 April 2022 in relation to the AGM to be held at The Function Room 1–2, 2/F., The Harbourview, 4 Harbour Road, Wanchai, Hong Kong (the “AGM Venue”) on Thursday, 2 June 2022 at 10:30 a.m.. Unless otherwise stated, capitalised terms used herein shall have the same meaning as defined in the Circular.

Having considered the relaxation of social distancing measures recently announced by the Government of the Hong Kong Special Administrative Region (the “Hong Kong Government”) (including lifting the prohibition on holding physical general meetings by companies), the AGM will be held in the AGM Venue as scheduled. In order to safeguard the health of the AGM attendees and to comply with the requirements for prevention and control of the spreading of COVID-19, save as the precautionary measures set out in the Circular, the following precautionary measures will also be implemented by the Company at the AGM Venue:

- i. The number of seats in the AGM Venue will be limited in accordance with the prevailing requirements or guidelines published by the Hong Kong Government and/or regulatory authorities at the time of the AGM to maintain social distancing. In view of this, the seats will be assigned on a first come, first served basis. The Company may limit the number of attendees at the AGM as may be necessary to avoid over-crowding.
- ii. All attendees are required to scan the “LeaveHomeSafe” venue and vaccination QR codes and comply with the Vaccine Pass requirements by presenting his/her valid vaccination, exemption or recovery record as required under the directions issued pursuant to the Prevention and Control of Disease (Vaccine Pass) Regulation (Chapter 599L of the Laws of Hong Kong), prior to entry into the AGM Venue.

- iii. All Shareholders, proxies, corporate representatives and other attendees who (a) are, or have been in close contact with any person who is, subject to any Hong Kong Government prescribed compulsory quarantine (including home quarantine); (b) are subject to any Hong Kong Government prescribed testing requirement or direction and have not tested negative; (c) have, or have been in close contact with anyone who has, contracted COVID-19, have been tested preliminarily positive of COVID-19 or are suspected of contracting COVID-19; or (d) exhibit any respiratory infection symptoms or are apparently unwell, may be denied entry into the AGM Venue and be asked to leave the AGM Venue.
- iv. Any other additional precautionary measures in accordance with the prevailing requirements or guidelines of the Hong Kong Government and/or regulatory authorities, or as considered appropriate in light of the development of the COVID-19 pandemic.

To the extent permitted under applicable laws of Hong Kong, the Company reserves the right to deny entry into the AGM Venue or require any person to leave the AGM Venue in order to ensure the health and safety of the attendees at the AGM.

The Company would like to remind all Shareholders that physical attendance in person at the AGM is not necessary for the purpose of exercising voting rights. As an alternative to attending the AGM in person, Shareholders are strongly encouraged to consider appointing the chairman of the AGM as their proxy to vote on the relevant resolutions at the AGM by completing and returning the form of proxy in accordance with the instructions printed thereon.

Subject to the development of the COVID-19 situation in Hong Kong and changes in any of the COVID-19 related regulations, the Company may be required to change the meeting arrangements for the AGM at short notice. Shareholders are advised to check the websites of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the Company (www.touyunbiotech.com.hk) for further announcement(s) and update(s) on such arrangements.

By order of the Board
Touyun Biotech Group Limited
Wang Liang
Chairman

Hong Kong, 27 May 2022

As at the date of this announcement, the Board comprises:

Executive Directors

Mr. Wang Liang (*Chairman*)

Mr. Du Dong

Non-executive Directors

Mr. Chen Hui

Ms. Tian Yuze

Mr. Zhang Lele

Mr. Jia Wenjie

Independent Non-executive Directors

Mr. Cheung Wing Ping

Mr. Ha Kee Choy Eugene

Mr. To Shing Chuen

Mr. Hu Guohua